These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31907572)

  • 1. Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases.
    Vallet N; Ertault M; Delaye JB; Chalopin T; Villate A; Drieu La Rochelle L; Lejeune J; Foucault A; Eloit M; Barin-Le Guellec C; Hérault O; Colombat P; Gyan E
    Ann Hematol; 2020 Feb; 99(2):229-239. PubMed ID: 31907572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval.
    Gauchy AC; Kanagaratnam L; Quinquenel A; Gaillard B; Rodier C; Godet S; Delmer A; Durot E
    Hematol Oncol; 2020 Aug; 38(3):326-333. PubMed ID: 32270502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
    Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
    Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
    Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
    Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
    Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma.
    Berger MD; Branger G; Leibundgut K; Baerlocher GM; Seipel K; Mueller BU; Gregor M; Ruefer A; Pabst T
    Leuk Res; 2015 Jun; 39(6):561-7. PubMed ID: 25890431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma.
    Abadi U; Peled L; Gurion R; Rotman-Pikielny P; Raanani P; Ellis MH; Rozovski U
    Leuk Lymphoma; 2019 Dec; 60(12):2922-2926. PubMed ID: 31167584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
    Gaut D; Romero T; Oveisi D; Howell G; Schiller G
    Hematol Oncol; 2020 Feb; 38(1):38-50. PubMed ID: 31674036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
    Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
    Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
    Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma.
    Cao Y; Liu Z; Wu W; Qian Y; Shi Q; Shen R; Ouyang B; Xu P; Cheng S; Ye J; Lu Y; Wang C; Yang C; Wang L; Zhao W
    Front Med; 2019 Feb; 13(1):94-103. PubMed ID: 30706260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.
    Kim SW; Asakura Y; Tajima K; Iwai T; Taji H; Chou T; Morishima Y; Suzumiya J; Sakamaki H; Suzuki R; Fukuda T
    Int J Hematol; 2020 Feb; 111(2):256-266. PubMed ID: 31732878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
    Van Den Neste E; Schmitz N; Mounier N; Gill D; Linch D; Trneny M; Bouadballah R; Radford J; Bargetzi M; Ribrag V; Dührsen U; Ma D; Briere J; Thieblemont C; Bachy E; Moskowitz CH; Glass B; Gisselbrecht C
    Bone Marrow Transplant; 2017 Feb; 52(2):216-221. PubMed ID: 27643872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients.
    Luo H; Yi P; Wang W; Li K; Meng L; Li J; Zeng W; Tang M
    Med Sci Monit; 2019 Nov; 25():8671-8682. PubMed ID: 31734687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
    Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.